全文获取类型
收费全文 | 10793篇 |
免费 | 1246篇 |
国内免费 | 237篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 42篇 |
妇产科学 | 191篇 |
基础医学 | 437篇 |
口腔科学 | 136篇 |
临床医学 | 1176篇 |
内科学 | 1200篇 |
皮肤病学 | 50篇 |
神经病学 | 104篇 |
特种医学 | 181篇 |
外国民族医学 | 49篇 |
外科学 | 820篇 |
综合类 | 1464篇 |
预防医学 | 302篇 |
眼科学 | 81篇 |
药学 | 1092篇 |
10篇 | |
中国医学 | 406篇 |
肿瘤学 | 4505篇 |
出版年
2024年 | 19篇 |
2023年 | 265篇 |
2022年 | 318篇 |
2021年 | 709篇 |
2020年 | 657篇 |
2019年 | 561篇 |
2018年 | 536篇 |
2017年 | 610篇 |
2016年 | 544篇 |
2015年 | 584篇 |
2014年 | 870篇 |
2013年 | 806篇 |
2012年 | 694篇 |
2011年 | 783篇 |
2010年 | 544篇 |
2009年 | 591篇 |
2008年 | 539篇 |
2007年 | 458篇 |
2006年 | 383篇 |
2005年 | 338篇 |
2004年 | 282篇 |
2003年 | 221篇 |
2002年 | 157篇 |
2001年 | 138篇 |
2000年 | 141篇 |
1999年 | 106篇 |
1998年 | 82篇 |
1997年 | 59篇 |
1996年 | 44篇 |
1995年 | 51篇 |
1994年 | 35篇 |
1993年 | 23篇 |
1992年 | 21篇 |
1991年 | 10篇 |
1990年 | 15篇 |
1989年 | 8篇 |
1988年 | 10篇 |
1987年 | 9篇 |
1986年 | 6篇 |
1985年 | 13篇 |
1984年 | 7篇 |
1983年 | 12篇 |
1982年 | 3篇 |
1981年 | 7篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1976年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
Proteomic Profiling of Small Extracellular Vesicles Isolated from the Plasma of Vietnamese Patients with Non-Small Cell Lung Cancer Reveals Some Potential Biomarkers 下载免费PDF全文
Thao Phuong Bui Phuong Lan LeLinh Thi Tu Nguyen Le Trung ThoThai Hong Trinh 《Asian Pacific journal of cancer prevention》2022,23(6):1893-1900
Background: Considering the poor prognosis of non-small cell lung cancer (NSCLC), the objective of this study was to examine the potential of plasma-derived vesicles as a source of lung cancer-specific proteins. Extracellular vesicle (EV) cargos are specific to the source cells, hence they have the potential of being a source of cancer-specific proteins. Methods: The proteins differently expressed in cancer were determined and derived from EVs isolated from the plasma of NSCLC patients at the National Lung Hospital. To this end, purification was done using gel filtration chromatography and ultracentrifugation. In addition, nano liquid chromatography mass spectrometry (LC–MS/MS) was used for analyzing. Results: Fifty-seven EV-derived proteins related to NSCLC were highlighted in this research. Some of them have not been addressed before, such as EEF1A1 (elongation factor 1-α1), KPNB1 (Importin subunit beta 1), SRC (proto-oncogene tyrosine-protein kinase) and ACTC1 (actin, alpha cardiac muscle 1). This list was further confirmed through a comparison with ExoCarta and Vesiclepedia. Conclusion: This study is the first work to show the involvement of several novel proteins of small EV (EEF1A1, KPNB1, SRC, and ACTC1) in the progression of NSCLC. The results suggested that they could serve as novel biomarkers for non-small cell lung cancer in the future. 相似文献
2.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献3.
目的 探究醛糖还原酶和晚期糖基化终末产物受体对糖尿病视网膜病变神经元凋亡的影响。方法 Wistar大鼠36只,随机分为对照组、模型组、转染组,后两组建立糖尿病大鼠模型。模型建立成功后,构建含有晚期糖基化终末产物受体siRNA的质粒并利用慢病毒转染入转染组大鼠体内。造模后4周、8周、12周,记录各组大鼠体质量及空腹血糖。造模后9周,禁食6 h,测定口服葡萄糖耐量。造模后12周,处死全部大鼠后,TUNEL法检测各组大鼠视网膜神经元凋亡情况,荧光分光光度计测定醛糖还原酶活性,Western blotting法测定晚期糖基化终末产物受体的表达,RT-PCR检测视网膜中Bcl-2和Bax mRNA相对表达量。结果 造模后4周、8周、12周,转染组和模型组的大鼠体质量均低于对照组(均为P<0.05);造模后12周,转染组大鼠体质量高于模型组(P<0.05)。造模后4周、8周、12周,各组内大鼠空腹血糖水平均无明显变化(均为P>0.05),转染组和模型组大鼠的空腹血糖水平均高于对照组(均为P<0.05)。模型组和转染组大鼠在口服葡萄糖后30 min时,血糖水平均高于对照组(均为P<0.05);在120 min时分别下降至最低,但仍高于对照组(均为P<0.05)。模型组和转染组的视网膜神经元凋亡指数、醛糖还原酶活性、晚期糖基化终末产物受体和Bax mRNA相对表达量均高于对照组(均为P<0.05),且转染组均高于模型组(均为P<0.05)。模型组和转染组的Bcl-2 mRNA相对表达量均低于对照组(均为P<0.05),转染组低于模型组(P<0.05)。结论 晚期糖基化终末产物结合受体后产生大量的氧自由基损伤,可能是导致糖尿病视网膜神经元凋亡,进而导致糖尿病视网膜病变发生的机制之一。 相似文献
4.
5.
目的调查镇江市各医院护士分层培训及分层进阶的方法及现状。方法2018年4—5月间采用自行设计的调查问卷,对全市医院的护理人员进行随机抽样调查。结果调查显示镇江市96.45%的护士受医院分层培训及分层进阶这一模式的管理。其中N1占16.77%,N2占29.5%,N3占41.9%,N4占8.7%,其他占3.11%。有24.53%的护士对医院目前的分层培训方式感到满意并认为无需改进,40.99%的护士表示满意,但需要改进,29.19%的护士表示基本满意,需要改进,5.28%的护士表示不满意需要较大改进。95.82%的医院科室对不用层级的护士有不同的核心能力要求并根据不同核心能力要求进行培训。结论护士分层培训几分层进阶这一管理模式在镇江各医院都有体现,但各医院实行的方式有较大差异,配套的管理方式也有待完善。 相似文献
6.
7.
Robert J. Motzer MD Bernard Escudier MD Saby George MD Hans J. Hammers MD PhD Sandhya Srinivas MD Scott S. Tykodi MD PhD Jeffrey A. Sosman MD Elizabeth R. Plimack MD Giuseppe Procopio MD David F. McDermott MD Daniel Castellano MD Toni K. Choueiri MD Frede Donskov MD PhD Howard Gurney MD Stéphane Oudard MD Martin Richardet MD PhD Katriina Peltola MD PhD Ajjai S. Alva MD Michael Carducci MD John Wagstaff MD Christine Chevreau MD Satoshi Fukasawa MD Yoshihiko Tomita MD PhD Thomas C. Gauler MD Christian K. Kollmannsberger MD Fabio A. Schutz PhD James Larkin MD PhD David Cella PhD M. Brent McHenry PhD Shruti Shally Saggi BEng Nizar M. Tannir MD 《Cancer》2020,126(18):4156-4167
8.
Sebastian P. Mondaca MD Dazhi Liu PharmD BCOP Jessica R. Flynn Sandy Badson Stefan Hamaway BS Mrinal M. Gounder MD Danny N. Khalil MD PhD Alexander E. Drilon MD Bob T. Li MD MPH Komal L. Jhaveri MD Alison M. Schram MD Katherine E. Kargus RN Mary Kate Kasler DNP MSN Natalie M. Blauvelt Neil H. Segal MD PhD Marinela Capanu PhD Margaret K. Callahan MD PhD David M. Hyman MD Maya Gambarin-Gelwan MD James J. Harding MD 《Cancer》2020,126(22):4967-4974
9.
10.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801